^(153)Sm-EDTMP治疗前列腺癌内分泌治疗后骨转移骨痛的效果评价

Evaluation of ^(153)Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy

目的:评价153Sm-EDTMP(153钐-乙二胺四甲撑膦酸)对前列腺癌患者行内分泌治疗后骨转移灶骨痛的治疗效果。方法:选择18例前列腺癌已行双侧睾丸切除术+口服福至尔治疗3～6个月、骨转移灶及骨痛未缓解患者,用153Sm-EDTMP治疗,153Sm-EDTMP用量为37MBq/kg体重.次,1次/月×(3～6)个月。密切观察骨痛缓解情况,治疗3个月后行骨扫描了解骨转移灶情况。结果:18例患者中14例骨痛有不同程度缓解,占77.8%,骨扫描示骨转移灶客观反应率为55.5%(10/18)。结论:对晚期前列腺癌、在行内分泌治疗后存在骨转移顽固性骨痛患者,153Sm-EDTMP内放射治疗仍有较好效果。

Objective： To evaluate the effect of Samarium etramthylene phosphoric acid （ ^153Sm-EDTMP ） in the treatment of painful bony metastases from prostate cancer after hormone therapy. Methods： 18 patients after being treated with hormone therapy （excision of testes＋flutamide） for 3-6 months and with painful bony metastases from prostate cancer were injected ^153Sm-EDTMP （dosage：37MBq/kg）,After the patients underwent 1-3 dose treatment.The palliation of pain and change of bone metastases on bone scans were evaluated. Results： A significant decrease of bone pain was achieved, making up 77.8% （14/18） and X ray and bone radionuclide imaging exam showed that 2 patients achieved complete focus disappearance, and 8 patients achieved partial focus disappearance. The response rate is 55.5%.Conclusion：^153Sm-EDTMP radiotherapy is efficacious to the refractory painful bone metastases in prostate cancer.